|
FI903489A0
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
SE509359C2
(sv)
|
1989-08-01 |
1999-01-18 |
Cemu Bioteknik Ab |
Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
|
|
WO1992002551A1
(en)
|
1990-08-02 |
1992-02-20 |
B.R. Centre Limited |
Methods for the production of proteins with a desired function
|
|
ATE427968T1
(de)
|
1992-08-21 |
2009-04-15 |
Univ Bruxelles |
Immunoglobuline ohne leichtkette
|
|
DE69426527T2
(de)
|
1993-06-09 |
2001-08-30 |
Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno, Delft |
Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen
|
|
US6091639A
(en)
|
1993-08-27 |
2000-07-18 |
Kabushiki Kaisha Toshiba |
Non-volatile semiconductor memory device and data programming method
|
|
EP0739981A1
(en)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
|
EP1469883A2
(en)
|
1998-02-19 |
2004-10-27 |
Xcyte Therapies, Inc. |
Compositions and methods for regulating lymphocyte activation
|
|
WO1999050461A1
(en)
|
1998-03-30 |
1999-10-07 |
Northwest Biotherapeutics, Inc. |
Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
|
|
CA2921260A1
(en)
|
1999-12-24 |
2001-06-28 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
US6741957B1
(en)
|
2000-07-21 |
2004-05-25 |
Daimlerchrysler Corporation |
Analytical tire model for vehicle durability and ride comfort analysis
|
|
US7018812B2
(en)
|
2000-11-03 |
2006-03-28 |
Duke University |
Modified G-protein coupled receptors
|
|
US7211395B2
(en)
|
2001-03-09 |
2007-05-01 |
Dyax Corp. |
Serum albumin binding moieties
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
US20060073141A1
(en)
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
US7253007B2
(en)
|
2001-11-30 |
2007-08-07 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
US7871619B2
(en)
|
2001-11-30 |
2011-01-18 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
US7442512B2
(en)
|
2001-11-30 |
2008-10-28 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
KR100599789B1
(ko)
|
2001-12-03 |
2006-07-12 |
삼성에스디아이 주식회사 |
방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
|
|
US20050214857A1
(en)
|
2001-12-11 |
2005-09-29 |
Algonomics N.V. |
Method for displaying loops from immunoglobulin domains in different contexts
|
|
WO2003066830A2
(en)
|
2002-02-08 |
2003-08-14 |
Genetastix Corporation |
Human monoclonal antibodies against membrane proteins
|
|
US7211240B2
(en)
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
|
EP3299393A1
(en)
|
2002-11-08 |
2018-03-28 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
AU2003286002B2
(en)
|
2002-11-08 |
2011-06-16 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
GB0228210D0
(en)
|
2002-12-03 |
2003-01-08 |
Babraham Inst |
Single chain antibodies
|
|
CA2507004A1
(en)
|
2002-12-03 |
2004-06-17 |
Celltech R & D Limited |
Assay for identifying antibody producing cells
|
|
US7432330B2
(en)
|
2002-12-31 |
2008-10-07 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
|
AU2003264053A1
(en)
|
2003-08-12 |
2005-03-10 |
William M. Yarbrough |
Treatment for acne vulgaris and method of use
|
|
EP1658500B1
(en)
|
2003-08-20 |
2012-04-18 |
UCB Pharma, S.A. |
Methods for obtaining antibodies
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
|
EP1871807B1
(en)
|
2005-02-18 |
2012-11-28 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cxcr4 and methods of use thereof
|
|
ES2434852T3
(es)
|
2005-04-21 |
2013-12-17 |
Chemocentryx, Inc. |
Anticuerpos que se unen a CCX-CKR2
|
|
CN103254309B
(zh)
|
2005-05-18 |
2017-09-26 |
埃博灵克斯股份有限公司 |
针对肿瘤坏死因子α的改进的纳米体TM
|
|
RU2433139C2
(ru)
*
|
2005-05-20 |
2011-11-10 |
Аблинкс Н.В. |
Nanobodies tm для лечения заболеваний, опосредованных агрегацией
|
|
EP1934259A2
(en)
|
2005-10-11 |
2008-06-25 |
Ablynx N.V. |
Nanobodies and polypeptides against egfr and igf-ir
|
|
WO2007055823A2
(en)
|
2005-10-28 |
2007-05-18 |
Multispan, Inc. |
Gpcr expressing cell lines and antibodies
|
|
EP2314590A1
(en)
|
2005-11-10 |
2011-04-27 |
ChemoCentryx, Inc. |
Substituted quinolones and methods of use
|
|
EP2010568A1
(en)
|
2006-04-14 |
2009-01-07 |
Ablynx N.V. |
Dp-78-like nanobodies
|
|
US20070269422A1
(en)
*
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
JP2010500876A
(ja)
*
|
2006-08-18 |
2010-01-14 |
アブリンクス エン.ヴェー. |
Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
|
|
JP2010502208A
(ja)
|
2006-09-08 |
2010-01-28 |
アブリンクス エン.ヴェー. |
半減期の長い血清アルブミン結合タンパク質
|
|
US8088895B2
(en)
*
|
2006-10-18 |
2012-01-03 |
Chemocentryx, Inc. |
Antibodies that bind CXCR7 epitopes
|
|
JP4810411B2
(ja)
|
2006-11-30 |
2011-11-09 |
東京応化工業株式会社 |
処理装置
|
|
CA2671581A1
(en)
|
2006-12-05 |
2008-06-12 |
Ablynx N.V. |
Peptides capable of binding to serum proteins
|
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
WO2008074839A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
|
CN102089325A
(zh)
|
2008-04-17 |
2011-06-08 |
埃博灵克斯股份有限公司 |
能够结合血清白蛋白的肽,以及包含其的化合物、构建体和多肽
|
|
BRPI0911984A2
(pt)
|
2008-05-16 |
2016-09-20 |
Ablynx Nv |
sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
|
|
US9034325B2
(en)
|
2008-07-22 |
2015-05-19 |
Ablynx N.V. |
Amino acid sequences directed against multitarget scavenger receptors and polypeptides
|
|
EP2352764B1
(en)
*
|
2008-10-14 |
2018-03-28 |
Ablynx N.V. |
AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
|
|
CN102257003B
(zh)
*
|
2008-12-19 |
2017-04-05 |
埃博灵克斯股份有限公司 |
用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
|
|
WO2010141986A1
(en)
*
|
2009-06-09 |
2010-12-16 |
Mabdesign Pty Ltd |
Novel antibodies and uses therefor
|
|
EP2531523A1
(en)
|
2010-02-05 |
2012-12-12 |
Ablynx N.V. |
Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
|
|
EP2552962B1
(en)
*
|
2010-03-26 |
2016-03-23 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
US20140228223A1
(en)
|
2010-05-10 |
2014-08-14 |
Andreas Gnirke |
High throughput paired-end sequencing of large-insert clone libraries
|